OR WAIT null SECS
February 23, 2022
Moderna and Thermo Fisher Scientific have formed a collaboration to leverage dedicated commercial fill/finish manufacturing capacity in the US for mRNA vaccines and therapies.
February 21, 2022
Recipharm has strengthened its biologics manufacturing capabilities with the acquisition of both Vibalogics and Arranta Bio.
February 17, 2022
Thermo Fisher Scientific is expanding its Millersburg, Penn., site with a $40 million investment to support increased production of single-use technology for critical vaccines and biologics.
February 11, 2022
Piramal Pharma Solutions plans to construct a multipurpose ADC manufacturing and aseptic fill/finish facility in Grangemouth, Scotland, and to upgrades its existing API manufacturing facility in Morpeth, England.
China-based CDMO Asymchem acquires US-based chemical technology company Snapdragon.
February 03, 2022
In this episode of Drug Digest, Chris Spivey, editorial director, and Meg Rivers, senior editor, dive into APIs, excipients, and formulation advances, specifically pairing the right APIs and excipients for optimizing formulations.
February 01, 2022
Arranta Bio will use Cytiva’s FlexFactory single-use manufacturing platform to produce mRNA vaccines.
Recipharm will build up its biologics service offering with the acquisition of GenIbet.
Industry experts share their top outsourcing tips from both the perspective of companies offering outsourcing services as well as for companies looking to outsource.
CDMOs need to consistently demonstrate agility as demand increases for newly developed therapeutic modalities.